| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
17β-Estradiol sulfate sodium targets estrogen receptors ERα and ERβ. The 17α-isomer binds weakly to estrogen receptors and exhibits little estrogenic activity in estrogen-responsive tissues. The compound binds to nuclear estrogen receptors, leading to receptor dimerization, translocation to the nucleus, and binding to estrogen response elements.
|
|---|---|
| ln Vitro |
17β-Estradiol sulfate (sodium) a steroid that is neuroactive[1][2].
In cell-free receptor binding assays, 17β-Estradiol sulfate sodium binds to estrogen receptors. The compound's binding affinity is influenced by the sulfate group, which alters its biological activity compared to the parent compound. The 17α-isomer shows weak binding to estrogen receptors. Cellular studies demonstrate that 17β-Estradiol sulfate sodium modulates gene transcription through estrogen receptor-mediated pathways. The compound enters the nucleus of target cells and regulates gene transcription leading to formation of messenger RNA. It also inhibits the growth of certain microorganisms. |
| ln Vivo |
In vivo, 17β-Estradiol sulfate sodium acts as a neuroactive estrogen with vasoprotective properties. The compound is involved in estrogen signaling pathways and affects various physiological processes. Its sulfated form has altered pharmacokinetics compared to the parent compound.
|
| Enzyme Assay |
Cell-free receptor binding assays for 17β-Estradiol sulfate sodium are performed using estrogen receptor preparations. Radioligand displacement studies use [³H]estradiol or other estrogen receptor ligands. Binding affinity is determined from competition binding curves. The compound's activity at ERα and ERβ can be assessed in separate assays.
|
| Cell Assay |
Cellular assays for 17β-Estradiol sulfate sodium are conducted using estrogen-responsive cell lines. Cells are treated with the compound, and reporter gene activity or endogenous gene expression is measured. ER-mediated transcriptional activity is assessed using luciferase reporter assays. Cell proliferation assays may also be used to assess estrogenic activity.
|
| ADME/Pharmacokinetics |
17β-Estradiol sulfate sodium has altered pharmacokinetics compared to its parent compound due to sulfation. The sulfate group enhances aqueous solubility but may reduce receptor binding affinity. The compound is metabolized through steroid metabolic pathways.
|
| Toxicity/Toxicokinetics |
17β-Estradiol sulfate sodium is a steroid hormone derivative with a well-established safety profile related to estrogen pharmacology. The compound's effects are mediated through estrogen receptor signaling pathways. Toxicity is dose-dependent and related to estrogenic activity.
|
| References | |
| Additional Infomation |
17β-Estradiol sulfate sodium is a research compound for studying estrogen receptor pharmacology and estrogen signaling. Its vasoprotective properties and neuroactive effects make it relevant for cardiovascular and neurological research. The compound is not approved for clinical use as a therapeutic agent.
|
| Molecular Formula |
C18H23NAO5S
|
|---|---|
| Molecular Weight |
374.43
|
| Exact Mass |
374.116
|
| CAS # |
4999-79-5
|
| PubChem CID |
23691039
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.823
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
25
|
| Complexity |
591
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+]
|
| InChi Key |
LMJQCTISQYSLPF-CMZLOHJFSA-M
|
| InChi Code |
InChI=1S/C18H24O5S.Na/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;/h3,5,10,14-17,19H,2,4,6-9H2,1H3,(H,20,21,22);/q;+1/p-1/t14-,15-,16+,17+,18+;/m1./s1
|
| Chemical Name |
sodium;[(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] sulfate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6707 mL | 13.3536 mL | 26.7073 mL | |
| 5 mM | 0.5341 mL | 2.6707 mL | 5.3415 mL | |
| 10 mM | 0.2671 mL | 1.3354 mL | 2.6707 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
